Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer

Next Previous
Trial Profile

A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Carcinoma; Early breast cancer; HER2 positive breast cancer
  • Focus Biomarker; Pharmacodynamics

Most Recent Events

  • 01 Jul 2026 Planned End Date changed from 1 Jun 2026 to 1 Jun 2027.
  • 22 Jun 2025 Planned End Date changed from 1 Jun 2025 to 1 Jun 2026.
  • 05 Mar 2025 Planned End Date changed from 1 May 2025 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top